GUD Knight Therapeutics

Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico

Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico

MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V.

Minjuvi® in combination with lenalidomide, followed by Minjuvi® monotherapy, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who are not eligible for autologous stem cell transplantation (ASCT).

DLBCL is the most common subtype of non-Hodgkin lymphoma, presenting an aggressive clinical profile. While a significant number of patients can be cured with standard front-line therapy, many will develop refractory disease or relapse following an initial response, and these individuals are often ineligible for ASCT. Such patients face a very poor prognosis, emphasizing the need for treatment options to improve their outcomes1.

The marketing authorization approval was based on the data from L-MIND trial, an open label, multicenter, single arm Phase 2 study, that evaluated Minjuvi® in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL ineligible for ASCT. The study primary analysis results demonstrated an objective response rate (ORR, primary endpoint) of 60%, including a complete response rate (CR) of 43% and a disease control rate (DCR) of 74%2. According to the 2025 National Comprehensive Cancer Network (NCCN) Guidelines, Minjuvi® is listed as one of the preferred second-line treatments for DLBCL patients who are ineligible for transplantation3.

“The treatment of DLBCL has significantly evolved in recent years, particularly in the relapse/refractory setting. I am glad to have more tools for our patients, as half of those who relapse after first-line therapy are not candidates for autologous transplantation. For these patients, there are new and effective options including Minjuvi®, achieving high rates of long-lasting responses. Approximately 57% of responding patients were still in remission at 5 years and, as a chemo-free regimen, the toxicity is low-grade and manageable”, said Dr. Luis Mario Villela, head of the clinical hematology and blood bank of CMDRICH Hospital and head of the Lymphoma and Myeloma of Ocaranza ISSSTE Hospital in Hermosillo, Sonora, Mexico. Dr. Villela is also a member of the National Investigators System level II and member of GELL group.

“Minjuvi® is an innovative product presenting clinically meaningful data in DLBCL and with exciting data in other rare lymphomas. We are thrilled to launch in another country and look forward to launching this product in additional markets in Latin America.” said Samira Sakhia, President and CEO of Knight.

In September 2021, Knight entered into a supply and distribution agreement with Incyte (NASDAQ: INCY), for the exclusive rights to distribute tafasitamab (sold as Monjuvi® in the United States and Minjuvi® in Europe) in Latin America. In October 2024, COFEPRIS, the Mexican health regulatory agency, granted regulatory approval through orphan medicine recognition for Minjuvi® in Mexico.

About Tafasitamab (Minjuvi®)

Minjuvi® (tafasitamab) is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP). MorphoSys and Incyte entered into: (a) in January 2020, a collaboration and licensing agreement to develop and commercialize tafasitamab globally; and (b) in February 2024, an agreement whereby Incyte obtained exclusive rights to develop and commercialize tafasitamab globally.

In the United States, Monjuvi® (tafasitamab-cxix) received accelerated approval by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for ASCT. In Europe, Minjuvi® (tafasitamab) received conditional Marketing Authorization from the European Medicines Agency in combination with lenalidomide, followed by Minjuvi® monotherapy, for the treatment of adult patients with relapsed or refractory DLBCL who are not eligible for ASCT.

XmAb® is a registered trademark of Xencor, Inc.

Monjuvi, Minjuvi, the Minjuvi and Monjuvi logos and the “triangle” design are registered trademarks of Incyte.

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at or .

Forward-Looking Statements for Knight Therapeutics Inc.

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2024, as filed on . Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

References:

  1. Duarte C, Kamdar M. Management Considerations for Patients With Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma. Am Soc Clin Oncol Educ Book. 2023 Jan;43:e390802.
  2. Duell, J et al. (2021). Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2021 Sep 1;106(9):2417-2426. doi: 10.3324/haematol.2020.275958
  3. National Comprehensive Cancer Network (NCCN) Guidelines. B-Cell Lymphomas dated February, 10, 2025. Accessible at:
CONTACT INFORMATION: 
  
Knight Therapeutics Inc. 
  
Samira SakhiaArvind Utchanah
President & Chief Executive OfficerChief Financial Officer
T: 514.484.4483T. +598.2626.2344
F: 514.481.4116 
Email: Email: 
Website: Website: 


EN
26/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Knight Therapeutics

 PRESS RELEASE

Knight Therapeutics Inc. ranks on The Globe and Mail’s sixth-annual Wo...

Knight Therapeutics Inc. ranks on The Globe and Mail’s sixth-annual Women Lead Here benchmark of executive gender diversity MONTREAL, March 28, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it will be recognized on The Globe and Mail’s 2025 Report on Business magazine’s sixth annual Women Lead Here list. This annual editorial benchmark identifies top-level Canadian businesses with the highest executive gender diversity. “We are both proud and humble to have Knight Therapeutics Inc. once again featured on the Globe and Ma...

 PRESS RELEASE

Thérapeutique Knight inc. se mérite une place à la sixième édition du ...

Thérapeutique Knight inc. se mérite une place à la sixième édition du classement Women Lead Here du Globe and Mail sur la diversité des femmes cadres MONTRÉAL, 28 mars 2025 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight » ou « la Société ») a le plaisir d’annoncer sa nomination à la sixième liste annuelle Women Lead Here du magazine Report on Business 2025 du Globe and Mail. Cette classification éditoriale annuelle recense les sociétés canadiennes de premier plan dont les cadres sont les plus diversifiés en matière de genre. « Nous éprouvons autant de fierté que ...

 PRESS RELEASE

Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexi...

Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V. Minjuvi® in combination with lenalidomide, followed by Minjuvi® monotherapy, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who are not eligible for autologous stem cell tran...

 PRESS RELEASE

Thérapeutique Knight annonce le lancement de Minjuvi® (tafasitamab) au...

Thérapeutique Knight annonce le lancement de Minjuvi® (tafasitamab) au Mexique MONTRÉAL, 26 mars 2025 (GLOBE NEWSWIRE) -- Thérapeutique Knight Inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (hors États-Unis), a annoncé aujourd’hui le lancement de Minjuvi® (tafasitamab) par sa filiale mexicaine, Grupo Biotoscana de Especialidad S.A. de C.V. Minjuvi® en association avec le lénalidomide suivi d’une monothérapie avec Minjuvi® est indiqué pour le traitement de patients adultes atteints d’un lymphome diffus à grandes cellules B (DLBCL) récidivant ou réfra...

 PRESS RELEASE

Knight Therapeutics Reports Fourth Quarter and Year-End 2024 Results

Knight Therapeutics Reports Fourth Quarter and Year-End 2024 Results Reports record-high revenues since inception MONTREAL, March 20, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2024. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. 2024 Highlights Financial results Revenues were $371,304, an increase of $43,105 or 1...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch